Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. (BCAX) Stock Price, Analysis & Data
| Bid | 18.74 |
| Market Cap | 1.63B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -185.36M |
| Beta | n/a |
| EPS (ttm) | -3.07 |
| PE Ratio (ttm) | n/a |
| Forward PE | -6.9 |
| P/B (ttm) | 3.59 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 10, 2026 |
| Ask | 32.75 |
| Volume | 346,965 |
| Avg. Volume (20D) | 744,006 |
| Open | 24.00 |
| Previous Close | 23.76 |
| Day's Range | 24.00 - 25.14 |
| 52-Week Range | 10.29 - 30.99 |
| Analyst | n/a |
| Price Target | 31 (25.30%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BCAX
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massac...
Financial Performance
In 2025, Bicara Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -137.95M, an increase of 102.88%.
Financial StatementsAnalyst Forecast
According to 13 analyst ratings, the average rating for BCAX stock is "null". The 12-month stock price forecast is 31, which is upside of 25.3% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
